![[U.S. Food and Drug Administration]](/peth04/20041108214317im_/http://www.fda.gov/icon/header.gif){kind=icon}
This document has been removed from our website because current information makes the Backgrounder incomplete. The Office of Special Health Issues is working with FDA's Division of Antiviral Drug Products, Center for Drug Evaluation and Research to update the information. We will place the updated version of the Backgrounder on this web address when it is completed.
If you have any questions, please E-mail the Office of Special Health Issues at oshi@oc.fda.gov
Last revised December 2000
Office of Special Health Issues, HF-12
![[OASHI HOME PAGE]](/peth04/20041108214317im_/http://www.fda.gov/icon/icnoashi.gif){kind=icon}